TARFINLAR owner Contact Information online
from NOVARTIS PHARMA AG
TARFINLAR
US serial number:85106759
Application filling date:Aug. 13, 2010
Register:Principal
Mark type:Trademark
Status:Registered. The registration date is used to determine when post-registration maintenance documents are due.
Status date:Jun. 14, 2011
Publication date:Mar. 29, 2011
Standard character claim:Yes. The mark consists of standard characters without claim to any particular font style, size, or color.
Mark drawing type:4 - STANDARD CHARACTER MARK
Foreign priority claimed:Yes
Foreign foreign application number:2554321
Foreign foreign application filling date:Jul. 28, 2010
Foreign foreign registration number:2554321
Foreign foreign registration date:Jul. 28, 2010
Foreign foreign application registration country:UNITED KINGDOM
Foreign foreign expiration date:Jul. 28, 2020
Goods and services:For: Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive
Current owner owner name:NOVARTIS PHARMA AG
Current owner owner address:LICHTSTRASSE 35
4056 BASEL
SWITZERLAND
07936
Current owner legal entity type:CORPORATION
Current owner state or country:SWITZERLAND
Attorney name:Angela L. Wilson
Attorney email:trademarks@gsk.com
Attorney docket number:PRJ/7057245/
Attorney email authorized:Yes
Correspondent name address:Angela L. Wilson
GlaxoSmithKline
Five Moore Drive
LGTM, C.3157.3D
Research Triangle Park,
NORTH CAROLINA
UNITED STATES
27709
Correspondent phone:919 483-0008
Correspondent email:trademarks@gsk.com
Correspondent fax:919 483-7988
Correspondent email authorized:Yes
Domestic representative name:Angela L. Wilson
Domestic representative phone:919 483-0008
Domestic representative fax:919 483-7988
Domestic representative email:trademarks@gsk.com
Domestic representative email authorized TARFINLAR:Yes
Latest trademarks
Popular owners
Glaxo Group Limited (173) Novartis AG (131) JOHNSON & JOHNSON (127) Millennium Pharmaceuticals, Inc. (55) Eli Lilly and Company (51) Windmill Health Products, LLC (47) Bayer Aktiengesellschaft (44) SANOFI (41) Wyeth LLC (41) Pfizer Inc. (39) Forest Laboratories, Inc. (34) Bristol-Myers Squibb Company (33) Vital Health Pharmaceuticals, Inc. (31) S. C. Johnson & Son, Inc. (30) Primary Investments Group Limited (28) MERCK SHARP & DOHME CORP. (27) Futurebiotics, LLC (26) Western Holdings, LLC (21) MONSTER ENERGY COMPANY (19) Scott Riddell (17)Popular publication dates
Mar. 29, 2011 Mar. 08, 2011 Mar. 15, 2011 Mar. 22, 2011 Nov. 16, 2010 Apr. 19, 2011 Apr. 12, 2011 Oct. 19, 2010 Oct. 26, 2010 Apr. 26, 2011 Feb. 15, 2011 Oct. 05, 2010 Oct. 12, 2010 Jan. 25, 2011 Sep. 21, 2010 Jan. 11, 2011 Feb. 22, 2011 Nov. 23, 2010 Sep. 28, 2010 Apr. 05, 2011Similar brands
